Good day, ladies and gentlemen, and welcome to your Pressure BioSciences second quarter investor conference call. All lines have been placed in a listen-only mode, and the floor will be open for your questions and comments following the presentation. If you should require telephone assistance throughout the conference, please press star then zero. At this time, it is my pleasure to turn the floor over to your host, Richard Schumacher. Sir, the floor is yours. Thank you, Melinda, and thanks, everybody, for joining us today for our second quarter financial review and business update. Before we begin, as always, I need to read a short cautionary statement. The following remarks may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, those detailed from time to time in the company's filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statement is based. As always, I'm pleased to welcome everybody on this call. I'm especially pleased because I get to welcome a new voice on our investor call today. This is the voice of John Hollister. John has worked with a number of people over the years and a number of companies that I know and came extremely well recommended from many of them. I've known him in the biotech and pharma space, as I said, for many years. He's worked with startups all the way to billion-dollar Goliaths. He's been very successful in those positions over the years. He's just sold his last company about two years ago, in which he was the CEO. While waiting to start his next adventure, I asked him for a little help. This is back in October of 2019. He said yes, and he gave us some part-time help, particularly in the marketing and sales area. In October 2020, we lost our director of sales and marketing, and I asked John B. Hollister if he'd come on board full time because he still was thinking about his new adventure and hadn't started it yet. To my delight, he agreed. As they say, the rest is history. All one needs to do is take a look at our results for the first and second quarter. This is the second-best back-to-back quarter in PBI's history. Of course, I asked John why it wasn't the best back-to-back, but that's a different story. It's the second-best back-to-back quarter we've had in our entire history. As they say, it's just the tip of the iceberg. Before we begin, John, I'd like to just welcome you. Hop on the microphone and please tell our listeners just a minute or so of your background. That would be helpful. Hey, Rick, thank you so much. It's really a pleasure to be speaking to your investors. Just for background, Rick touched on it. I can't believe that more than 30 years have passed since I graduated from Stanford and went into big pharma at SmithKline, where I was in a series of sales and marketing roles. That's where I started, predominantly in vaccines, biologics, and got a chance to launch a vaccine and also start a sales force in the U.K. Left there after eight years and looked at Amgen to help launch an oncology product called Neulasta, which did about $1 billion in its first year. I was made the global commercial lead in oncology, the first of those people, and got to help develop a number of different assets. After 15 years of big companies, I decided, like some of my friends, to go off and try the startup world. I've spent the last 17 years in leadership roles, including CEO of several pharmaceutical, medical device, and diagnostics companies both public and private. Got a lot of experience in doing that. As Rick mentioned, a couple of years ago, I'd already known Rick for a few years, and I had watched PBIO or Pressure BioSciences, was fascinated by the technology, and sounded like you needed a little help initially commercializing UltraShear technology. Since then, I've just fallen in love with all three platforms and very excited about where this company is because it really is a transformational period. The addition of agrochem is just icing on the cake. With that, I'll pass it back to Rick. Hey, thanks, John, I think everybody after listening to that can see why we're so excited to have you on board. This is transformational. This is quite a transformational year. We have so many things in the hopper. It's only going to get better, in our opinion. Take a look at what we've been doing so far, then think about UltraShear coming out. BaroFold is starting to catch fire. Of course, the agrochem, as you mentioned, that you've been a great help on with me, which I appreciate. All of these things are coming to fruition over the coming weeks, months, and by early next year. A guy like you is going to be very helpful to our company and to our investors with your experience. As you know, I hate to say it, but I keep praying that your next adventure doesn't start too soon because we need you here at PBI. For today's meeting, I'm going to start with a very brief discussion of the second quarter results, and then we'll highlight some of the accomplishments so far in this year, and then we're going to open it up for Q&A. On the financial side, of course, we have sent out the finances both in the Q and in a press release. There's no need to go through them in detail. I'm always available after the call. You guys know how to reach me, to take any questions you have, but it would be a shame not to highlight some of the terrific things that have happened both in the second quarter and the year-to-date. Just like the first quarter, we had a very strong second quarter. Our revenue was over $600,000, and it was up 127% over last year. Our instrument sales led the way up 178%. Our consumable sales were down 14%, but they started picking up right at the end of the quarter, we're not concerned. Of course, for the year so far, they're up a lot. BaroFold and UST, which right now is primarily BaroFold and it's a service, and it's up 298% over last year, and it's up over the first quarter, and it's starting to catch fire. Our operating loss, when you look at all these things and then you look and see that the operating loss went down over 50%, is just icing on the cake. We have a very strong across-the-board revenue increase. A lot of calls, a lot of desire for our products and our pressure-based core business. At the same time, we reduced our operating loss from $1.3 million down to $646,000 for the second quarter, and from $2.7 million down to $1.7 for the first half. We're certainly headed in the right direction. The numbers are just as good for the year-to-date because of the good first quarter. Again, once you look at them, if you have any questions either at the end of our brief prelude to the Q&A or anytime after, give me a call. I'll be happy to go through them. In terms of operational and technical highlights, we not only had a very strong quarter financially, but we had a very strong quarter operationally and on our technical business. We formed a new subsidiary in July, called PBI Agrochem. We feel we have a business that we can get into in the agrochemical space where I just saw today another chemical has been banned by the EPA for use on crops that are going into food. We put too many chemicals into our food. We put too many chemicals into our land. We're looking at eco-friendly agrochemicals. As everyone knows, with UltraShear technology, we can make these good products even better. We're not only going to be developing our own products, we're working on the acquisition of an existing product line that's sort of been off the market for a couple of years, and we're going to bring it back on. Terrific product line. It has a following, but just like new improved Tide, we can have new improved agrochemicals. Our UltraShear is going to play a big role in this, and about half of the agrochemicals, if not more, are oil-based, and that's where a nanoemulsification really helps. You can apply less and get a better effect in most cases. Speaking of nanoemulsification, over the last three to six months, we received three new patents, as everybody knows, for our UltraShear technology, which is the platform behind the nanoemulsification. We're very excited about this. We announced over $1 million in orders in the first month of setting up PBI agrochem. We've now rented a site out west, where we'll be doing the warehousing, processing, and packaging. We've already got a full-time employee. We already expect the first half a million dollars of bulk material that needs to come in and get processed and shipped out to happen this week or early next week, probably this week. We are in the business. The agrochemical business is a multi-billion-dollar business, but what's really needed there are green, eco-friendly compounds, and compounds that we can use less of and make them go further. We're very excited about what we're going to do in that space. John's been an enormous help because of his background. He and I have been working as a team on a lot of things so that you can be assured it's going to happen, most likely because not only is it on my shoulders, but it's also on John's shoulders. He's got terrific background, as you've already heard. Whether it's the agrochemical launch or it's UltraShear technology or even BaroFold, we pulled John into all three of those areas, and he's been a help over the last few months, actually six months, as a full-time employee. It's been great. Rick, if I could add a couple of thoughts. You may. on the agrochem business, because I'm very excited about it. I actually grew up on an avocado ranch, and my grandfather or grandmother were very large citrus growers. I'm very familiar firsthand with the agribusiness and the complexities of pesticides and fertilizers and actually product enhancers. These products are truly eco-friendly are revolutionary, but do, in fact, many of them employ different kinds of oils, natural oils, but they are effective in doing what they do, but they separate like your oil and vinegar does. The growers, whomever is handling the product, have to spend time in making certain that these 1,000-liter totes are mixed very thoroughly. When I say time, it can be upwards of an hour and 20 minutes with a little propeller in it. If that product sits for any period of time before it's dispensed, you have to re-stir it. If we make a nanoemulsion of that eliminates that step, or it has the potential to do so, which could be huge, in addition to, as Rick said, likely offer better penetration into the leaves or into the soil, or more effective in terms of encouraging bugs to leave, which are all the goals of the agrochem. What's been fascinating, because we've also spent some time on the CBD side and the cannabis side, is the potential use in the cannabis world for exactly the same reasons. There's a great deal of synergies that are appearing in work that we've already been doing that will apply from the agrochemicals world. Awesome. Thank you, John. At this point I think to acknowledge one or two more of the great things happen in the last four or five months. We reported on the successful nanoemulsification using our UltraShear technology of a compound called astaxanthin. Astaxanthin is basically accepted by almost everybody out there that I know as one of the world's most potent, some people say the most potent antioxidant. It comes out of algae and it's an oil, it's in an oil. Like many other things that are oil-based, we as humans and our pets, we're water-based, so oil-based compounds don't get absorbed very well. We looked at astaxanthin, we looked at CBD, we looked at many other oil-based compounds, Our UltraShear technology has been successful at nanoemulsifying and basically turning the oil drops into millions, if not billions, of tiny little nano-sized oil droplets, Therefore the active ingredient gets spread among millions, if not billions, of nano-sized oil droplets. That allows it to become dissolved in water in our bodies and transported throughout the body and allows the body to extract from that oil, those oil droplets very quickly, the active ingredient. The general concept is that with a nanoemulsion, you can generally get what is called bioavailability greater than 90%, that the active ingredient is available to the body in 90% or more, whereas with a macro or micro emulsion, such as your raspberry vinaigrette which doesn't mix very well, the amount of absorption is down to 6%, 10%, 12%. As John said, we can use less and make it go further. We're excited. John's been talking to three or four companies about astaxanthin in particular, and has taken that off of my table and has led discussions with some of the leading companies in the world with astaxanthin. We're not here to announce anything, but John, can you give us an idea? You're getting a lot of phone calls from people that are interested in UltraShear in multiple different areas, correct? Absolutely. The response is instantaneous from some of the biggest players in the industry. I think the first element is this nanotechnology allows an otherwise opaque liquid like astaxanthin or CBD, and it turns it absolutely clear. When the particle size gets this small, it no longer reflects light. The applications for CBD and astaxanthin are two examples, but the applications in pharmaceuticals, the nutraceuticals, in food processing, as well as the agrochemical side are just the tip of the iceberg. There are so many directions we can go, whether it's very high value, small volumes or much larger volumes. We're looking at processing a couple liters of fluid in a minute, which is a fairly large volume of anything. It gives you a very concentrated solution that you could then infuse any of these into a second product, for instance, a beverage, whether it's an antioxidant like astaxanthin or a kind of broad use product like a CBD. The list of potential customers who can utilize our technology is remarkable. We're balancing that as a smaller organization, but it's great to have the demand that's pulling us along. Back to you Rick. Rick before I turn it over now to Q&A, one more thing. I gave a short talk yesterday at something called Emerging Growth, and I believe it's out on YouTube now and you can see the 15 minutes. The bottom line here is we should all understand that this is a transformational year. That the revenue that we've seen, which is now more than double than what we saw last year, two terrific back to back in our core products, it's going to be additive now starting in the third quarter with our agrochemical products. Our BaroFold is already growing, and at the end of the year or early next year with our UltraShear products. It's exciting time now for Pressure Bio and for our investors. At this point, Melinda, I'd like to turn it over to our guests and take any questions if there are any. Thank you. The floor is now open for questions. If you do have a question, please press star then one on your telephone keypad to join the queue. If you're using a speakerphone, please pick up your handset to provide the best sound quality. Again, ladies and gentlemen, if you do have a question or comment, please press star then one on your telephone keypad at this time. First we go to Gary Zwetchkenbaum with Plum Tree Consulting. Please go ahead. Thank you, Rick. John, welcome aboard. I want to congratulate you as a team for fantastic quarter. With the comments that you made on these orders of over $1 million on the new agrochemical business, a two-part question. I'd like you, if you can, to discuss the effects of this new agrochem business, not only for Q3 and Q4, but as you alluded to, what would be 2022 and how you see it affecting profitability. If you would, talk about the goals. I know, and recently you mentioned a number of top goals that you have for the remainder of the year and 2022. If you would just mention the important ones, the ones you think we should be looking at. Thank you. Thank you, Gary. Thanks for the kind words. Your first question is about the impact of the agrochem to our financials going forward. We have gone out on the limb, as they say. We have said we expect to have a significant impact in the third quarter. We've already purchased a half a million dollars of inventory. We've already received over $1 million of orders for this material. How much of that will be shipped in the third quarter is up in the air. Let's just say that I believe that between a half a million and $1 million, somewhere in that, maybe $600,000, $700,000, $800,000 of that can be shipped in the third quarter and the rest we would expect to go into the fourth quarter. Also in several things we put out, I've mentioned that we believe that the orders are going to continue to come. We're working on orders as we speak. The $1 million, we don't expect this to be the only set of orders for the second half of this year. We're excited because this is additive to our existing core business. You can look at our existing core business and add to that in the third and fourth quarter, the $1 million worth of orders. I would say add some more to it because we expect that there'll be additional orders that we can fulfill in the third and probably more the fourth quarter. We're even looking at purchasing more bulk material that we will then be processing into finished goods in the next week or two. It's exciting. We're set up. We're prepared for this. We have a facility. It is ready to receive the bulk product, it's ready to process, it's ready to ship out. We are ready to go, and we have the first set of purchase material and processing equipment and the ability to ship it out. It will impact our third and fourth quarter. We're doing this sort of very quickly. I am hopeful that next year, where we have more time to plan, we can do even better next year than pulling in $1 million or $1 million plus in a quarter or two. In fact, I think our goal is to do much better than that next year. Again, transformational year. I think our investors, many of whom are on this call, are aware that we generally do $500,000, $600,000 a quarter in our core business. I think our core business is going to be growing from that number. On top of it, we're going to be adding at least, I think, the same amount and certainly we think next year even more from our agrochem. John, would you like to add anything to that? I think I would just echo it. Having looked at this business and seen the history of this eco-friendly product, that there is a significant pent-up demand. I know a lot of people who own vineyards and the wineries by and large, especially the more boutique-y, higher end out here in California, they all are trying to be eco-friendly and totally natural. There's a great appeal in the grape industry of not using toxic chemicals. In fact, in order to garner the label that you are actually organic is very challenging, and it requires having products like these. I'm really excited for the addition. Frankly, on the core business, we've seen a return to the labs both in academic centers and commercial people are actually going back to their offices and using the equipment and are now really gearing up to expand their labs. They are looking at their budgets for the rest of the year. I'm cautiously optimistic that we continue to see the return to our core business of work. Lastly, I've witnessed the transition in both UST and in BaroFold, where companies have gone from our first stage, which is proof of concept, and are moving into what we refer to as pilot scale. That's a big transition because that moves towards commercialization, from which we can then benefit as a partner in a royalty sense. Very exciting all around. Richard Schumacher, if I may, you mentioned yesterday at the Emerging Growth Conference, and you alluded to it a few minutes ago, not only from the $500,000 in material that you recently purchased, but for the $1 million in orders that you had, you were going to purchase additional materials. I think you talked about $300,000-plus possibly in the coming weeks in orders. How is this going to affect 2022 and profitability? Can you expand on that a little? We've gone out on a limb and said we believe that we'll become profitable as a company before the end of next year. Before the end of next year could be fourth quarter or it could be first or second quarter. We believe that this company is going to be profitable by the end of 2022 and as soon as possible in 2022. It depends on the UltraShear and it depends on the agrochem and on the BaroFold. Our PCT program is doing well. It did poorly the last couple of years. We can't keep enough product instruments in stock right now. It's a terrific problem to have. I'd much rather have a problem of how do I build more instruments and what do I do with these that I built six months ago? That's the problem we have right now is how do we build more instruments to take care of this demand, this pent-up demand that's all of a sudden started this year and it's real. Yes, we're looking forward to next year. The agrochem business is a business that does high revenue and has a good margin. With a high revenue and good margin, a lot of this should fall to the bottom line. That's why we feel comfortable in saying that we believe that this company will be profitable at some point next year with the combination of UltraShear and agrochem. We will be in the agrochem business. It's the eco-friendly organic agrochem, green, I should say, agrochem business. In the many other areas where UltraShear can be used, we won't be competing with our users. In those areas, we'll be making UltraShear available and looking for some type of continued stream of cash that's coming from the use of our incredible UltraShear platform. With that, we've teamed up with Ohio State, and things are going extremely well, and we're looking forward to getting UltraShear out and letting many other groups from many other industries use it. Rick and John, you should be commended, you and your team. I visited your office recently. What you've done in this short period of time with this new division is outstanding. I'm looking forward to the next two quarters and next year. Thanks a lot. Thank you. Briefly, we're not going to take up a lot of time, but Gary asked about the key, and I think they're important. I'll just mention a few. I think we put out eight bullets on things that were key goals of ours. Cleaning up the balance sheet is one. We've had a tough time over the last few years. We've had to take a lot of onerous debt to keep things moving forward, and we've done a good job of cleaning that up over the last year, one and a half. Part of this has been cleaned up by the debtors converting into stock, and part of it is by taking on additional debt, and that additional debt is much better debt. A lot of people say no debt's good, but a debt that is not nearly as onerous as the debt we took is better. We've taken on some debt and used that cash to pay off some of the more onerous debt. Our balance sheet is much cleaner than it was a year ago and much, much cleaner than it was two years ago. Our goal is over the next really couple of weeks to couple of months is to the only debt we want on the balance sheet is debt from some of the investors that we know are very strongly supportive of the company. If we need them to convert that debt into equity at some time, perhaps as a part of going on a national exchange, these are the people that we're getting the debt from now. We're cleaning up our balance sheet, and we've reduced. $3 million or $4 million of more onerous debt and replaced it with either using equity or using much better, much more friendly debt to do that. Moving up to Nasdaq or New York Stock Exchange is very high on our list. This is a company that deserves and demands and needs to be on a national exchange. We need to have institutional support. We don't have a single institution in this company as an investor. We need that institutional support. We need that broad base that Nasdaq and New York Stock Exchange will bring to us. It is a major goal. Remember, I've started three prior companies that were all Nasdaq. This company was Nasdaq until we got delisted only because our stock fell below $1. It is our goal to get this company back on Nasdaq. Once we do that, I think the wings can really open up, and this company can have a great chance to fly. It's a major goal of ours. We've got to finish the PBI agrochem and the acquisition of the assets of this other company that are just going to add to PBI agrochem. We've got to expand. We continue to expand our intellectual property. We've gotten five or six new patents in the last year or so. Our partnership with Ohio State is going to be very interesting come the fall because we have a consortium with them, and we're shipping out our prototype for industrial UltraShear machine, and we're going to be inviting a who's who list from around the world to join the consortium and come and see and use their product and see how it works on our prototype. There's so many of these things, and we've got to get UltraShear out by the end of the year or early next year. There's so many things that we have to do as a small company. It's guys like John, who've drunk the Kool-Aid and realized that this is a company that's transforming into a much different company going forward, coming on board to help me and help Jeff and help the team here. Yeah, it's a great feeling to have these goals and to know that they're all within reach. Next, we go to the line of private investor Tony Aggie. Please go ahead. Hi. Thanks for taking my call. I'm going to try to make this very, very quick. You spoke about the patents, and I was wondering, especially with the geopolitical situation as it is, you have patents and also a business in China, is that a possible concern? Also, do you have a strategy for those who are trying to short this company into the ground? Thank you. Thank you for the question, Tony. Number one, I'm not concerned about the issue you mentioned about the geopolitical issues that are going on. We do have business in China. It is not a large part of our business. We do have a major customer there who works with us, and through all of the issues back and forth, he's continued to work. He and his team have continued to work with us. I'm happy to say that China's important to us, but we're not dependent on China. We work with them, we work with them well. They work with us, and there's been no disruption from anything that's happened in the past, with the major group in China. We are all over the place. We have very good strongholds throughout Europe, Eurasia, throughout Central and South America, and Canada, of course, and the U.S. No, I don't see that as an issue at all. I can't really comment on the shorting. I know that I get phone calls every day, every week from investors who are concerned, who believe that the company, they look at how the activity is, and they believe that this company is being shorted. All I know, having started four publicly traded companies and been CEO of four publicly traded companies, actually three publicly traded companies, on the board of the fourth, is that the best way to beat the shorts is to beat them with revenue and profits. That's what we're going to do. We are going to transform this company. Whoever thinks that this company is a company that they've been beaten up for the last two, three, four, five years, they're going to be shown that they're wrong. This company is ready to break out. We've laid it out. We're very clear, and we're very confident, and we believe very strongly that it begins now. The transformation has already started. Tony, I won't talk about shorting because it's not something that I know much about. I just know how to beat shorts, and you beat shorts by delivering what investors expect us to deliver, and that's what we believe we're going to be doing and starting already. Thank you, Rick. I'm happy to hear that. Next, we have another private investor, Martin Joseph. Your line is open. Yes. Hi. Thanks for the call. I have questions related to, say, the astaxanthin and any other products that you might want to be pursuing with that. In the companies that you're reaching out to, do you find that it's the greater bioavailability that's the appeal to them or potentially using, say, less product? I guess you can call a premium supplement user. Looking at my astaxanthin now, there's 6 mg in there, so obviously it's not as bioavailable. Are companies looking to then reduce but then, say, have a branded sort of product astaxanthin that they would market to say, "Hey, you only need 2 mg of this." Are they thinking they'll still keep the six, but then they'll market the, you're getting more for that six than you would from another company? It's a great question for John, so I'm going to turn it over to John. John's been right in the front of the line talking to all of the companies that are calling us, and a lot of them have, about astaxanthins and other compounds. Yeah. Thank you for turning it over. It's also a great question. I'd have to answer it as this. I've had different attributes that people are pursuing from different companies. Astaxanthin, because it is actually relatively expensive, the cost of the goods sold, if you can limit or reduce the amount you need to achieve the same goals, and I think secondarily and importantly, if you're in the business, you will appreciate this, have a predictable dose. Many of these oils, when metabolized or broken down in the gut, are metabolized in different rates by different people. You really don't have the same dose for each person. Theoretically, or at least the data suggests, that when you make a nanoemulsion of these oils, you can actually much more deliberately deliver the dose that you want to deliver. The third attribute that I have found with astaxanthin, as well as CBD and several other products that we've made nanoemulsions, is the aesthetics. Because especially if whatever form the final product is, if it's a clear product, it's really nice to put in a clear, active agent. That's what we can do up to certain concentrations, but these concentrations seem to be adequate. It's not one particular attribute. It's different for different players. I think that's the best way to describe it. Thank you very much. Next, we go to the line of Geoffrey Scott with Scott Asset Management. Please go ahead. Rick, it's been a long time since we had that lobster roll together. Yeah, it has. I hope you've been well. It's been tough out there. It has. I'd like to drill down on the agrochem and get away from big numbers and talk about specific details. The $1 million in orders, how many different products is that $1 million of orders for how many different customers? Is it one order from one customer for $1 million worth of goods, or is it 10 orders for $100,000 each from 10 different customers? Is it going to commercial growers, or is it meant to be distributed through house and garden retail stores for use in a consumer's backyard garden? That kind of detail. Help us out with some of those nitty-gritty details, please. I will a little bit, Jeff. I'm not going to get into too much of the weeds here. I'll tell you, first of all, it's more in bulk with large growers right now. We have plans to go to more retail. Generally, in most cases, retail is more lucrative than bulk to large growers. We do some retail. In fact, we've already shipped some product, I think two or three, to retailers. The bulk product is generally what we're going to be doing. It's not going to be 100 customers at $10,000 a piece. It's going to be more like 5-1 0 customers at $100,000-$200,000 a piece, in that range. Without getting into the nitty-gritty, I think right now it's going to be larger amounts going to bigger users. We have our eye on the small retail customer, because that's where it can get very lucrative. We can provide a product that's much needed, and the same product, the same cost, we can get more of a payback for it. John, you want to add to that? John, are you there? Sorry about that. Yeah, I was stuck on mute there for a moment. Yeah, the agrochem business, as you may or may not know, is driven and dominated by some very large distributors who are to the central valleys of the growing areas, that then distribute to large agribusiness and small farms, the combination of the two. Those agricultural distributors are definitely familiar with this product, and we look to see them as good customers. There's also a second group, and almost it's as if you use either direct sale or drop ship sale of these very large volume, literally 1,000-liter totes of chemicals that are either sprayed through the water systems or sprayed on top of the plants, depending on which product it is. To Rick's point, we see a portion of the business in consumer-oriented products, which definitely are at a higher value or higher margins to us. The large bulk shipments are going to be, at least for the first couple of years, the core of our business. Very large shipments in 18-wheel trucks that drive it out either directly to the farm or directly to the distributor. I hope that helps. Yeah, that's helpful. That $1 million of orders, is that for one product, or do you have multiple products that are going out? There's several products in there. It's not like 20 products. The growing season and what's growing is different all the time. Some of the products are needed now, some of the products are needed in November. That's good, because we don't want to be seasonal, where the majority of our agrochemical products are all sent in a three-month period. We have products for every season. You'll see that this season right now that we're going into, will have its own set of products that's needed. The next season will need its own set of products. We have products that are already made, some of which we think we can make in the future even better, make good things even better, for each of the seasons that come. Whether it's corn or soybeans or grapes or whatever it is, we hope to have products being shipped out basically 12 months a year. All right. Can you tell us exactly what the product does? I'll tell you what, Geoffrey. An insecticide, a herbicide, what kind of benefit does it give that grower? We have fertilizers, we have pesticides that are all eco-friendly. It's a combination. I'm not trying to evade your question. We're in the middle or near the end of negotiations with certain people, so we've got to keep some things close to the vest. I know you understand that. Perhaps in our call in three months, we can be maybe even taking down the product line itself, so to speak. Right now, we can't do that. We have a lot of IP that's based on this, which is trade secret-driven and not patents-driven. We want to be careful what we say, because we haven't finished the acquisition, but we're doing some of those work ourselves right now. When you think about the growth stimulants that we put this into, a couple of press releases, the pest treatment, things like that, finishing products that are going on to things like grapes or other plants or other fruit. It's a combination, which is good, because it makes it much more broad-based. Okay, good luck. I will hold my breath for another three months. Thanks, Rick. Thank you. You're very patient, Geoffrey, and we appreciate it. Okay. That does appear to be all the signals we have today. We'll turn back to Richard Schumacher for closing remarks. First of all, John, thank you for joining us, and I'm glad that our investor base was able to meet you and see your very impressive background and know that you're part of the team now, which is very helpful to me in particular, because a day doesn't go by where I don't pick up the phone and say, "John, I need you to help me out on this." It's great to have someone who's gone through what I go through as a CEO and especially CEO of a public company. John, publicly, in front of everyone, thank you very much. Don't think about starting your own thing for the time being. For everybody else, I just thank you for taking time, and as you know, I'm always available at the other end of the phone. This is an exciting time. I think the old phrase, "The best is yet to come," in our case, we believe it's absolutely true. We've had a terrific two quarters. We had a tough year last year, and we've had a tough two or three years for different reasons, but we've had a great start to 2021. We believe we're going to have a much better ending, and it's always great when you have a better ending to a great start. We think this is our transformational year. We believe that all the things that we've put into motion over the last few years are coming to fruition, and then on top of it, the icing on the cake is this opportunity in agrochem, which we have taken advantage of. Exciting times. It makes it easy to go to bed late and get up early and come into work because it's all moving in the right direction and everybody on this phone call who's an investor has every right to. You've been patient. Those of you who've been with us for years, and I know some of you have, you've been very patient, and we're working very hard to get a return for everybody, the new investor, and especially the investor that's helped us out for years now. Thank you. Thank you. This does conclude today's teleconference. We thank you for your participation. You may disconnect your lines at this time. Have a great day.